Valeo Pharma Future Growth
Future criteria checks 1/6
Valeo Pharma is forecast to grow earnings and revenue by 45.7% and 19.5% per annum respectively while EPS is expected to grow by 50.1% per annum.
Key information
45.7%
Earnings growth rate
50.1%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | 19.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
10/31/2025 | 76 | -12 | N/A | N/A | 1 |
10/31/2024 | 61 | -18 | N/A | N/A | 1 |
1/31/2024 | 54 | -28 | -8 | -3 | N/A |
10/31/2023 | 54 | -28 | -21 | -16 | N/A |
7/31/2023 | 53 | -28 | -20 | -24 | N/A |
4/30/2023 | 45 | -27 | -32 | -25 | N/A |
1/31/2023 | 37 | -26 | -37 | -31 | N/A |
10/31/2022 | 28 | -26 | -35 | -29 | N/A |
7/31/2022 | 18 | -24 | -33 | -20 | N/A |
4/30/2022 | 18 | -22 | -25 | -23 | N/A |
1/31/2022 | 16 | -18 | -22 | -19 | N/A |
10/31/2021 | 14 | -14 | -16 | -12 | N/A |
7/31/2021 | 12 | -9 | -14 | -12 | N/A |
4/30/2021 | 8 | -7 | -10 | -7 | N/A |
1/31/2021 | 8 | -5 | -8 | -6 | N/A |
10/31/2020 | 7 | -5 | -7 | -5 | N/A |
7/31/2020 | 7 | -4 | -5 | -4 | N/A |
4/30/2020 | 8 | -2 | -5 | -4 | N/A |
1/31/2020 | 6 | -4 | -5 | -4 | N/A |
10/31/2019 | 7 | -4 | -3 | -2 | N/A |
7/31/2019 | 7 | -3 | -3 | -2 | N/A |
4/30/2019 | 7 | -3 | -2 | -2 | N/A |
1/31/2019 | 6 | -3 | -2 | -1 | N/A |
10/31/2018 | 4 | -2 | -2 | -1 | N/A |
7/31/2018 | 3 | -3 | -1 | -1 | N/A |
10/31/2017 | 1 | -4 | N/A | -1 | N/A |
10/31/2016 | 1 | -1 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VP2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VP2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VP2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VP2's revenue (19.5% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: VP2's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VP2's Return on Equity is forecast to be high in 3 years time